[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369257-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369257-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","covid-19-lockdown-related-treatment-modifications-did-not-impact-the-outcome-of-digestive-cancers-the-clin-covidica-prospective-study","COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers - the Clin-COVIDICA prospective study","","The COVID-19 pandemic altered worldwide cancer care pathways, yet prospective long-term evidence on these therapeutic modifications in digestive cancers remained limited. Clin-COVIDICA followed consecutive digestive cancer patients receiving oncologic treatment from March 1 to April 30, 2020, for 24 months. Among 401 patients, 13.7% underwent therapeutic modifications. In those on palliative treatment, modifications showed a significant longer progression-free survival and no significant overall survival detriment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/covid-19-lockdown-related-treatment-modifications-did-not-impact-the-outcome-of-digestive-cancers-the-clin-covidica-prospective-study/369257/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/covid-19-lockdown-related-treatment-modifications-did-not-impact-the-outcome-of-digestive-cancers-the-clin-covidica-prospective-study/369257.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the aim of the Clin-COVIDICA prospective study?","Question",{"text":63,"@type":64},"To determine the clinical impact of COVID-19-related therapeutic modifications in patients with digestive cancer at the study center over 24 months.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were therapeutic modifications defined and how many patients received them?",{"text":68,"@type":64},"Among 401 included patients, 55 (13.7%) underwent therapeutic modifications, most commonly switching to an oral drug, treatment holidays, or treatment cancellation.",{"name":70,"@type":61,"acceptedAnswer":71},"Did therapeutic modifications affect survival outcomes?",{"text":72,"@type":64},"Overall, no negative survival impact was observed. For patients receiving palliative treatment, progression-free survival was significantly longer with therapeutic modifications, while overall survival showed no significant difference.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369257,1790707928,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Randrian et al. BMC Cancer (2025) 25:398 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-13787-9](https://doi.org/10.1186/s12885-025-13787-9)  \nRESEARCH Open Access  \nCOVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA  \nprospective study  \nViolaine Randrian 1*†, Amale Dhimene2†, Armelle Pillet3, Camille Evrard3, Rayan Elfadel4, Claire Boyer 1, Astrid Guyotd’Asnières de Salins 1, Isabelle Ingrand5, Aurélie Ferru3, Laetitia Rouleau 1 and David Tougeron 1  \nAbstract  \nBackground The Coronavirus Disease 2019 (COVID-19) pandemic modified the organization of cancer care pathways worldwide. Few prospective long-term data assessing these therapeutic modifications are available.  \nMethods Clin-COVIDICA was a prospective cohort aiming at determining the clinical impact of COVID-19-related therapeutic modifications in patients with digestive cancer in our center. All consecutive patients undergoing an oncologic treatment for a digestive cancer from March 1 to April 30, 2020, were enrolled in the cohort and followed-up for 24 months. The primary endpoint was progression-free survival (PFS) . Secondary endpoints included COVID-19 rate, adverse events (AE) and overall survival (OS) . Survival curves were estimated using the Kaplan-Meier method and compared by the log-rank test.  \nResults Of the 401 patients included, 39 . 6% were female, mean age was 68 years old and most frequent tumor were colorectal (50 . 0%) and pancreatic (17 . 9%) cancers. All in all, 55 patients (13 . 7%) have undergone therapeutic modifications. The most frequent were a switch to an oral drug (capecitabine, 30 . 9%), treatment holidays (29 . 1%) and treatment cancellation (18 . 2%) . Considering patients with palliative treatment (n = 339), there was a non-significant trend for longer OS (52 . 0 months versus 36.4 months, p = 0 . 07) and a significant longer PFS (15 .4 months versus 6.2 months, p = 0 . 009) in patients with therapeutic modifications. There were more all grades AEs in patients without therapeutic modifications (84 .4% vs. 65. 5%, p = \u003C 0. 001), but more severe AEs (grade 3–5) among patients with therapeutic modifications (18 . 2% versus 8 . 7%, p = 0 . 048), especially for patients with a switch to an oral drug, which resulted in 8 severe adverse events and one death. Six patients (1 . 5%) had a COVID-19, with one COVID-19-related death and one definitive cancellation of a curative surgery due to the consequences of COVID-19 .  \n†Violaine Randrian and Amale Dhimene contributed equally to this work.  \n*Correspondence:  \nViolaine Randrian [violaine.randrian@chu-poitiers.fr](violaine.randrian@chu-poitiers.fr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nRandrian et al. BMC Cancer (2025) 25:398 Page 2 of 10  \nDiscussion We observed no negative survival impact of therapeutic modifications due to th","cbCaipZdOdcNhsPQ","https://ap.wps.com/l/cbCaipZdOdcNhsPQ","pdf",1407286,"English","# Abstract\n## Background\n## Methods\n## Results\n## Discussion\n## Trial registration\n# Introduction","[{\"question\":\"What is the aim of the Clin-COVIDICA prospective study?\",\"answer\":\"To determine the clinical impact of COVID-19-related therapeutic modifications in patients with digestive cancer at the study center over 24 months.\"},{\"question\":\"How were therapeutic modifications defined and how many patients received them?\",\"answer\":\"Among 401 included patients, 55 (13.7%) underwent therapeutic modifications, most commonly switching to an oral drug, treatment holidays, or treatment cancellation.\"},{\"question\":\"Did therapeutic modifications affect survival outcomes?\",\"answer\":\"Overall, no negative survival impact was observed. For patients receiving palliative treatment, progression-free survival was significantly longer with therapeutic modifications, while overall survival showed no significant difference.\"}]","COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers - the Clin-COVIDICA prospective study | PDF",1790181636,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8b9d3661fb6f6d466c74674a625e854.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2336017041645034c80feb710453b18c.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f4a31f81d26e8b0237c0944f595af60.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03a74705cd6d4e29ba52b7cee8443e94.webp",980,1306]